

Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB

Xintela AB announces today that the company is changing its Certified Adviser to Västra Hamnen Corporate Finance AB.

Xintela AB has entered into an agreement with Västra Hamnen Corporate Finance AB regarding the role as Certified Adviser. Västra Hamnen Corporate Finance AB will assume the role of Certified Adviser on June 1, 2026. Until then, Tapper Partners AB will continue to act as the company's Certified Adviser.

Contacts

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela ([XINT](#)) is a publicly-traded clinical-stage biopharma company developing cutting edge medical products in stem cell therapy and targeted cancer therapy. Xintela's proprietary technology uses the stem cell marker integrin $\alpha 10\beta 1$ to select and quality-assure stem cells in the product XSTEM[®], which has shown safety and positive efficacy in a clinical study on knee osteoarthritis and has completed a clinical study on difficult-to-heal leg ulcers. Xintela's in-house GMP-facility manufactures XSTEM and provides process development and manufacturing of other cell therapies. Xintela's wholly owned subsidiary Targinta AB develops First-in-Class therapeutic antibodies targeting integrin $\alpha 10\beta 1$. TARG9, an Antibody-Drug Conjugate (ADC), and TARG10, a function blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers including glioblastoma, triple-negative breast cancer and sarcoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm. Xintela's Certified Adviser is Tapper Partners AB.

Press Release
28 May 2026 13:00:00 CEST



Attachments

[Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB](#)